Halotherapy for Respiratory Health: Asthma, Allergies, and COPD

Respiratory conditions affect hundreds of millions of people worldwide. Asthma alone impacts approximately 25 million Americans (CDC, 2023), and COPD affects an estimated 16 million diagnosed Americans with millions more undiagnosed. For those seeking complementary approaches alongside standard medical treatment, halotherapy has attracted growing interest. But the evidence requires careful examination, and 2025-2026 research has added new data points worth considering.

What Changed in 2025-2026

Before diving into the full breakdown, here's what's new since our last update:

• 2025 ARDS trial: A prospective randomized controlled trial of 97 patients with acute respiratory distress syndrome found halotherapy significantly improved lung function (FVC and FEV1) and reduced inflammatory biomarkers associated with pyroptosis (inflammatory cell death). Published in Discover Medicine (Springer Nature, 2025).
• 2025 post-COVID speleotherapy study: A Frontiers in Medicine study of 46 post-COVID patients found speleotherapy did not significantly improve lung diffusion capacity (DLCO), even in a subgroup with impaired baseline function. A reminder that not all salt-based therapies work for all respiratory conditions.
• GOLD 2026 COPD guidelines: The updated Global Initiative for Chronic Obstructive Lung Disease report emphasizes pulmonary rehabilitation, exercise training, and telerehabilitation as complementary therapies. Halotherapy is not included among recommended non-pharmacological approaches.
• GINA 2025 asthma update: The Global Initiative for Asthma continues to focus on biologic therapies and biomarker-guided treatment. Halotherapy is not addressed in the guidelines.
• Ongoing RCT (NCT06250452): A registered clinical trial evaluating halotherapy's effect on children with asthma is in progress. Results have not yet been published.

How Halotherapy Affects the Respiratory System

The Mucolytic Effect

The primary mechanism by which inhaled salt particles benefit the airways:

• Dry salt particles (1-10 microns) land on the airway lining
• Through osmosis, salt draws water from underlying tissue into the airway lumen
• This increases the volume and decreases the viscosity of airway mucus
• Thinner, more hydrated mucus is easier to clear through coughing and mucociliary transport
• For conditions characterized by excessive or thick mucus (COPD, bronchiectasis, cystic fibrosis), this mucus thinning is directly therapeutic

Clinical parallel: Nebulized hypertonic saline (3-7% salt solution) is an FDA-approved treatment for cystic fibrosis and bronchiectasis, based on this same osmotic mucus-thinning mechanism. Halotherapy applies a related principle through dry aerosol rather than liquid nebulization. For a deeper comparison of these delivery methods, see our halotherapy vs nebulizer guide.

Anti-Inflammatory Action

• Salt particles may reduce inflammation in bronchial tissues
• The 2025 ARDS trial found halotherapy alleviated pyroptosis-related biomarkers (inflammatory cell death markers), providing the strongest RCT-level evidence to date for this mechanism
• A 2022 systematic review of 13 studies also reported reduced inflammatory markers in halotherapy patients with chronic respiratory conditions
• Reduced airway inflammation can decrease swelling, open constricted airways, and reduce mucus production

Antibacterial Properties

• Salt at sufficient concentrations creates a hostile environment for bacteria and viruses
• Inhaled salt particles may disrupt the living environment of pathogens in the airways
• This could reduce the frequency of respiratory infections that trigger asthma exacerbations and COPD flare-ups
• The antibacterial effect is well-documented for salt in other contexts (wound care, food preservation) but less studied specifically for halotherapy aerosol

Airway Hydration

• The salt-induced fluid secretion hydrates dry, irritated airways
• Improved airway hydration supports normal mucociliary function
• This may be particularly relevant for people in dry climates or who use heated indoor air that dries the airways

Understanding the difference between dry and wet salt therapy matters here, as each delivers these mechanisms differently.

Halotherapy for Asthma

What the Evidence Shows

Positive Findings:

• A pilot RCT published in Pediatric Pulmonology (2017) found children with mild asthma showed improved lung function after 7 weeks of halotherapy, with no adverse effects reported
• The 2021 umbrella review of 18 studies found modest improvements in PEFR and FEV1 measurements across respiratory patients
• A survey-based study of chronic allergenic respiratory patients found positive responses to halotherapy chamber treatment
• Multiple observational studies from Eastern European countries (where halotherapy has been practiced longer) report symptom improvement in asthma patients

Limitations:

• Only one study in the umbrella review met rigorous RCT criteria
• Most asthma-halotherapy studies are observational with small sample sizes
• Placebo effect and relaxation benefits cannot be ruled out
• Long-term outcomes (reduced exacerbation frequency, reduced medication needs) are not well-studied
• AAFA reviewed 151 articles on salt therapy and found just one randomized controlled trial meeting their standards

The Bronchoconstriction Risk

This is the most important safety consideration for asthma patients:

• Inhaling any particulate matter, including salt, can trigger bronchoconstriction (airway narrowing) in people with hyperresponsive airways
• AAFA warns that "inhaling concentrated salts (hypertonic saline) has been proven to irritate the airways, causing cough and mucus, which can make asthma worse"
• A member of AAFA's Medical Scientific Council stated that halotherapy "has not been rigorously studied, despite claims from 'experts'"
• The risk appears highest in patients with severe or poorly controlled asthma
• Mild asthma patients are generally at lower risk

For a full rundown of potential reactions, read our guide to halotherapy side effects.

Safety protocol for asthmatic patients:

1. Consult your pulmonologist before starting halotherapy
2. Carry your rescue inhaler to every session
3. Start with shorter sessions (15-20 minutes) at lower salt concentrations
4. Monitor peak flow before and after sessions
5. Discontinue and consult your physician if symptoms worsen

Halotherapy for Allergies

Allergic Rhinitis

• Salt's anti-inflammatory and mucolytic properties could theoretically reduce nasal congestion and drainage
• Saline nasal irrigation (neti pots, saline sprays) is well-established for allergic rhinitis. Halotherapy delivers salt through a different route
• Anecdotal reports from halotherapy users frequently include improved nasal breathing and reduced allergy symptoms
• Formal clinical trials specific to allergic rhinitis and halotherapy are lacking

Seasonal Allergies

• Some halotherapy advocates recommend beginning regular sessions 4-6 weeks before allergy season
• The theory is that improved mucus clearance and reduced airway inflammation prepare the respiratory system for allergen exposure
• No controlled studies have tested this preventive approach
• We cover this topic in depth in our halotherapy for seasonal allergies guide

What the Evidence Supports

The evidence for halotherapy specifically for allergies is weak to moderate:

• The mechanisms are plausible (mucolytic, anti-inflammatory)
• Anecdotal reports are positive
• Clinical trials specific to allergies are absent
• The related practice of saline nasal irrigation has strong evidence for allergies, lending indirect support to the halotherapy mechanism

Halotherapy for COPD

Potential Benefits

COPD is characterized by chronic bronchitis (mucus overproduction) and emphysema (alveolar destruction). Halotherapy may address the mucus component:

• Mucus clearance: COPD patients often struggle with thick, excessive mucus. The osmotic effect of inhaled salt may thin this mucus, making it easier to expectorate. A 2022 systematic review of 13 studies found halotherapy improved forced expiratory volume, forced vital capacity, and peak expiratory flow in patients with chronic respiratory diseases.
• Infection prevention: COPD patients are vulnerable to respiratory infections that trigger exacerbations. Salt's antibacterial properties could theoretically reduce infection frequency.
• Reduced inflammation: Chronic airway inflammation is a hallmark of COPD. The 2025 ARDS trial demonstrated measurable anti-inflammatory effects (reduced pyroptosis biomarkers) in a randomized setting, providing indirect support for this mechanism in chronic conditions.

What the Evidence Shows

• Observational studies report reduced exacerbation frequency and improved quality of life in COPD patients using halotherapy
• A 2007 study found COPD patients had fewer symptoms and better quality of life after halotherapy sessions compared to control groups receiving standard care only
• A 2014 systematic review found most COPD-halotherapy studies were methodologically flawed, with only one RCT meeting strict inclusion criteria
• Lung function improvements (FEV1, PEFR) have been reported but not consistently
• The GOLD 2026 report does not include halotherapy among recommended non-pharmacological COPD treatments. Recommended complementary approaches include pulmonary rehabilitation, exercise training, telerehabilitation, and nutritional support.

Important Considerations for COPD Patients

• COPD patients should continue all prescribed medications (inhalers, oxygen therapy)
• Halotherapy may complement but cannot replace pulmonary rehabilitation
• Exacerbation during or after halotherapy should prompt immediate medical attention
• Start with lower salt concentrations and shorter sessions
• Learn more about how often to schedule sessions for your specific situation

What Medical Organizations Say (Updated 2026)

American Lung Association

"Halotherapy, or salt therapy, is touted as an alternative treatment for lung problems such as asthma, bronchitis, and cough. However, there is not enough evidence to recommend halotherapy as a treatment." Their position has not changed as of 2026.

Asthma and Allergy Foundation of America (AAFA)

AAFA states that halotherapy is "likely safe" for most asthma patients but recommends erring on the side of caution. Their Medical Scientific Council notes that halotherapy "has not been rigorously studied" and that inhaling concentrated salts can irritate airways and make asthma worse. They do not recommend it as a treatment.

GOLD 2026 (COPD Guidelines)

The Global Initiative for Chronic Obstructive Lung Disease 2026 report emphasizes evidence-based complementary therapies: pulmonary rehabilitation, exercise training, smoking cessation, vaccination, and nutritional support. Halotherapy is not mentioned in the guidelines.

GINA 2025 (Asthma Guidelines)

The Global Initiative for Asthma 2025 update focuses on biologic therapies, T2 biomarkers, and stepped care. Halotherapy is not addressed.

European Respiratory Traditions

Some European respiratory institutions remain more receptive to halotherapy as a complementary therapy, reflecting a longer tradition of speleotherapy (cave therapy) in countries like Poland, Romania, and Ukraine. However, the 2025 Frontiers in Medicine study on speleotherapy for post-COVID patients from Germany found no significant therapeutic benefit for lung diffusion capacity.

The Research Landscape: Where Things Stand

The quality and quantity of halotherapy research has improved modestly, but significant gaps remain:

The 2025 ARDS trial is the largest and most rigorous RCT to date (97 patients), but it studied acute respiratory distress syndrome, not chronic conditions like asthma or COPD. Generalizing those results to chronic respiratory patients requires caution.

For the latest summary of clinical data, see our halotherapy research roundup.

A Practical Protocol for Respiratory Conditions

If pursuing halotherapy as a complementary approach (with physician approval):

Phase 1: Trial (Weeks 1-3)

• Frequency: 2-3 sessions per week
• Duration: 30-45 minutes
• Monitoring: Track symptoms, peak flow readings, medication use
• Goal: Assess tolerance and initial response
• Read: What to expect at your first salt cave visit

Phase 2: Therapeutic Course (Weeks 4-10)

• Frequency: 3-5 sessions per week
• Duration: 45 minutes
• Monitoring: Continue tracking metrics
• Goal: Accumulate therapeutic benefit

Phase 3: Maintenance (Ongoing)

• Frequency: 1-3 sessions per week
• Duration: 45 minutes
• Goal: Maintain benefits achieved during the therapeutic course
• Budgeting: Check our session cost guide for pricing expectations

Frequently Asked Questions

Can halotherapy cure asthma or COPD?

No. Asthma and COPD are chronic conditions that require ongoing medical management. Halotherapy may provide symptomatic relief and improve quality of life as a complementary approach, but it does not address the underlying disease process. The GOLD 2026 guidelines and GINA 2025 guidelines do not include halotherapy among recommended treatments. Never discontinue prescribed treatments for halotherapy.

Is halotherapy the same as using a nebulizer with saline?

Related but different. Nebulized hypertonic saline delivers a concentrated liquid salt solution directly to the airways through a mouthpiece. Halotherapy delivers dry salt aerosol at lower concentrations through ambient room air. Nebulized saline has a stronger evidence base and is FDA-approved for specific conditions like cystic fibrosis and bronchiectasis. Halotherapy is a wellness practice without FDA approval. We compare these two approaches in detail in our halotherapy vs nebulizer guide.

What did the 2025 ARDS study actually find?

The 2025 study published in Discover Medicine (Springer Nature) was a prospective RCT of 97 patients with acute respiratory distress syndrome. Patients receiving halotherapy showed significant improvements in FVC (forced vital capacity) and FEV1 (forced expiratory volume) compared to conventional treatment alone. The halotherapy group also showed reduced pyroptosis-related inflammatory biomarkers. This is the largest RCT of halotherapy to date, though it studied ARDS specifically, not chronic asthma or COPD.

How does halotherapy compare to salt water gargling for sore throats?

Salt water gargling delivers salt directly to the throat and upper airway through liquid contact. Halotherapy delivers microscopic dry salt particles through the entire respiratory tract via inhalation. They work through similar osmotic and antibacterial mechanisms but differ in delivery method and target area.

Should I stop my inhaler before a halotherapy session?

No. Continue all prescribed medications as directed by your physician. Some people find they can discuss reducing medication with their doctor after sustained improvement, but this decision belongs to your physician, not to you or the halotherapy facility.

The Evidence Summary

Halotherapy has a plausible mechanism for respiratory benefit and a growing body of supportive evidence. The 2025 ARDS trial is the strongest RCT to date, demonstrating measurable improvements in lung function and inflammatory markers in a controlled setting. But the quality of evidence for chronic respiratory conditions (asthma, COPD, allergies) still does not meet the standards required for medical recommendation.

The strongest case remains for its mucolytic effects (thinning mucus), which parallel the established use of nebulized saline. Major medical organizations (ALA, AAFA, GOLD, GINA) have not changed their positions, and halotherapy remains absent from clinical practice guidelines.

For people with respiratory conditions, halotherapy may serve as a useful complementary practice alongside standard medical treatment, provided it is pursued with physician knowledge and appropriate safety monitoring. Check our complete halotherapy guide for a broader overview of what salt therapy can and can't do.

Related Reading

• Halotherapy Benefits: What Research Says About Salt Therapy
• Halotherapy Side Effects: What to Know Before You Go
• Salt Cave Therapy for Children: Is It Safe?

-- The Salt Cave Finder Team